Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Accurately reflects the boxed warning/Section 5.1 language that Qelbree is associated with higher rates of suicidal thoughts and behaviors versus placebo in ADHD patients, and correctly emphasizes close monitoring especially early in treatment and during dosage changes, consistent with Sections 5.1, 8.4, and 17.
Category Scores
Accurate Statements
Qelbree is associated with higher rates of suicidal thoughts and behaviors in pediatric and adult ADHD patients compared with placebo.
Supported by Section 5.1 (higher rates reported in pediatric and adult ADHD patients vs placebo).
Patients should be monitored closely—especially early in treatment and during dosage changes.
Supported by Section 5.1 (closely monitor, especially during the initial few months and at times of dosage changes) and reinforced by Section 8.4 and Section 17 counseling.
Unsupported Statements
Contradictions
Important Omissions
The label’s additional detail that patients should also be monitored for precursor symptoms (e.g., insomnia, irritability, depressed mood, anxiety, agitation, akathisia, mania/hypomania, panic attacks, impulsive behavior, aggression) and that caregivers should report symptoms immediately.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statement matches the label’s key safety message (higher rates vs placebo and close monitoring early and during titration) without adding unlabelled claims; it omits some precursor-symptom detail but does not contradict labeling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label’s precursor-symptom examples and caregiver reporting instructions (present in Sections 5.1, 17).
Suggested Improvement
Include that monitoring should cover precursor symptoms and that patients/caregivers should report emergent suicidal thoughts/behaviors promptly, particularly early in treatment and during dose adjustments.